Literature DB >> 30309291

Don't Sugar Coat It: Glycemic Control in the Intensive Care Unit.

Kara Stoudt1, Sanjay Chawla1.   

Abstract

Stress hyperglycemia is the transient increase in blood glucose as a result of complex hormonal changes that occur during critical illness. It has been described in the critically ill for nearly 200 years; patient harm, including increases in morbidity, mortality, and lengths of stay, has been associated with hyperglycemia, hypoglycemia, and glucose variability. However, there remains a contentious debate regarding the optimal glucose ranges for this population, most notably within the past 15 years. Recent landmark clinical trials have dramatically changed the treatment of stress hyperglycemia in the intensive care unit (ICU). Earlier studies suggested that tight glucose control improved both morbidity and mortality for ICU patients, but later studies have suggested potential harm related to the development of hypoglycemia. Multiple trials have tried to elucidate potential glucose target ranges for special patient populations, including those with diabetes, trauma, sepsis, cardiac surgery, and brain injuries, but there remains conflicting evidence for most of these subpopulations. Currently, most international organizations recommend targeting moderate blood glucose concentration to levels <180 mg/dL for all patients in the intensive care unit. In this review, the history of stress hyperglycemia and its treatment will be discussed including optimal glucose target ranges, devices for monitoring blood glucose, and current professional organizations' recommendations regarding glucose control in the ICU.

Entities:  

Keywords:  critical illness; glucose; hyperglycemia

Year:  2018        PMID: 30309291     DOI: 10.1177/0885066618801748

Source DB:  PubMed          Journal:  J Intensive Care Med        ISSN: 0885-0666            Impact factor:   3.510


  7 in total

Review 1.  Central metabolic interactions of immune cells and microbes: prospects for defeating infections.

Authors:  Ana Traven; Thomas Naderer
Journal:  EMBO Rep       Date:  2019-06-21       Impact factor: 8.807

2.  Correlation Analysis of Blood Glucose Level with Inflammatory Response and Immune Indicators in Patients with Sepsis.

Authors:  Qi Wei; Jinglin Zhao; Hao Wang; Cuicui Liu; Caihong Hu; Chao Zhao; Qingchun Dai; Zhi Hui; Rui Wang
Journal:  Dis Markers       Date:  2022-05-26       Impact factor: 3.464

Review 3.  Issues for the management of people with diabetes and COVID-19 in ICU.

Authors:  Antonio Ceriello; Eberhard Standl; Doina Catrinoiu; Baruch Itzhak; Nebojsa M Lalic; Dario Rahelic; Oliver Schnell; Jan Škrha; Paul Valensi
Journal:  Cardiovasc Diabetol       Date:  2020-07-20       Impact factor: 9.951

Review 4.  Type 2 diabetes mellitus and sepsis: state of the art, certainties and missing evidence.

Authors:  Elisa Costantini; Massimiliano Carlin; Massimo Porta; Maria Felice Brizzi
Journal:  Acta Diabetol       Date:  2021-05-10       Impact factor: 4.280

5.  Corticosteroid Administration and Impaired Glycemic Control in Mechanically Ventilated COVID-19 Patients.

Authors:  David J Douin; Martin Krause; Cynthia Williams; Kenji Tanabe; Ana Fernandez-Bustamante; Aurora N Quaye; Adit A Ginde; Karsten Bartels
Journal:  Semin Cardiothorac Vasc Anesth       Date:  2021-09-02

6.  Identifying potential biomarkers and therapeutic targets for dogs with sepsis using metabolomics and lipidomics analyses.

Authors:  Brett Montague; April Summers; Ruchika Bhawal; Elizabeth T Anderson; Sydney Kraus-Malett; Sheng Zhang; Robert Goggs
Journal:  PLoS One       Date:  2022-07-08       Impact factor: 3.752

Review 7.  Challenges in hyperglycemia management in critically ill patients with COVID-19.

Authors:  Rajesh Kethireddy; Darshan Gandhi; Asim Kichloo; Love Patel
Journal:  World J Crit Care Med       Date:  2022-07-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.